Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integral Diagnostics Ltd. ( (AU:IDX) ) has shared an update.
Integral Diagnostics has confirmed that incoming Managing Director and Chief Executive Officer Jason Martinez will commence his role on 6 August 2026, following an extended garden leave period with his former employer. The timing finalises a key leadership change for the ASX-listed medical imaging group, providing clarity to investors and staff on the transition schedule.
Incumbent MD and CEO Dr Ian Kadish will remain in his position until Martinez takes over to ensure a seamless handover and operational continuity. This planned overlap is designed to support stability across IDX’s Australia and New Zealand imaging network, limiting disruption to day-to-day operations and reinforcing confidence among clinicians, patients and other stakeholders during the leadership transition.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.20 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Limited (IDX) is a leading provider of medical imaging services across Australia and New Zealand. The company operates under a medical leadership model that brings together radiologists and diagnostic imaging specialists to deliver high-quality patient care, service and access in the diagnostic imaging sector.
Average Trading Volume: 862,223
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$905.7M
For a thorough assessment of IDX stock, go to TipRanks’ Stock Analysis page.